When does the Pemazyre (pemigatinib) patent expire?
The exact “patent expiry” date for Pemazyre depends on which specific patent(s) and which country or jurisdiction you mean (for example, U.S. vs. EU vs. UK). The provided information does not include the patent numbers or jurisdictions needed to calculate or confirm a specific expiry date.
Does Pemazyre have any exclusivity that extends beyond patent expiry?
Even if a core patent expires, drug exclusivity can continue via mechanisms such as regulatory exclusivity terms or other related IP (for example, additional patents covering formulations, methods, or specific claims). To determine whether that applies to Pemazyre, you would need the relevant jurisdiction(s) and the specific patent family/patent numbers being tracked.
How can I find the exact Pemazyre patent expiry date for a specific country?
To get the correct expiry date, search for:
1) The Pemazyre patent family tied to pemigatinib in the target country’s patent database (or a commercial patent-expiry tracker).
2) Country-specific regulatory exclusivity records for pemigatinib.
3) Any patent term adjustments, pediatric extensions, or later-filed continuation/secondary patents that may shift the effective “last-to-expire” date.
Why the “expiry date” can differ across sources
Different trackers sometimes report different dates, because they may use:
- The earliest expiring patent in a family vs. the last-to-expire patent.
- Application/publication dates vs. granted patent expiration.
- The U.S. vs. EPO/UK/EU national phase outcomes.
What to do if you’re trying to assess biosimilar/generic entry timing
Generic entry timing is usually governed by the “last-to-expire” protections (patents and regulatory exclusivity). The exact answer again depends on jurisdiction and which pemigatinib patents are still active.
If you tell me the jurisdiction, I can narrow it down
Which country (e.g., U.S., EU, UK, Canada, Japan) are you asking about, and do you want:
- earliest patent expiry,
- last-to-expire patent in the family,
or
- overall launch/competition timing (patent + exclusivity)?